Earendil Labs announced it has raised $787 million in private funding, marking one of the largest biotech financing rounds in recent years. The US-headquartered company, which has roots in China, plans to use the funds to advance its AI-driven drug discovery platform. The company is also considering a potential initial public offering.
The funding highlights growing investor interest in AI-powered drug discovery, as traditional pharmaceutical development faces mounting costs and lengthy timelines. Earendil's platform represents the convergence of artificial intelligence and biotechnology, two of the most capital-intensive sectors in the innovation economy.